Author's response to reviews

Title: Boceprevir for Previously Untreated Patients with Chronic Hepatitis C Genotype 1 Infection: A US-Based Cost-Effectiveness Modeling Study

Authors:

S. A. Ferrante (shannon_ferrante@merck.com)
J. Chhatwal (chhatwal@pitt.edu)
C. A. Brass (clifford_brass@aol.com)
A. C. El Khoury (Antoine_el_khoury@merck.com)
F. Poordad (fred.poordad@cshs.org)
J.-P. Bronowicki (jp.bronowicki@chu-nancy.fr)
E. H. Elbasha (Elamin_elbasha@merck.com)

Version: 6 Date: 5 March 2013

Author's response to reviews: see over
March 5, 2013

Philippa Harris, PhD
Executive Editor
BMC-series Journals
BioMed Central
Floor 6, 236 Gray's Inn Road
London, WC1X 8HL

Subject: MS: 1213417687727327 - Boceprevir for Previously Untreated Patients with Chronic Hepatitis C Genotype 1 Infection: A US-Based Cost-Effectiveness Modeling Study

Dr. Harris:

Please find the attached updated manuscript titled “Boceprevir for Previously Untreated Patients with Chronic Hepatitis C Genotype 1 Infection: A US-Based Cost-Effectiveness Modeling Study”. This version of the manuscript addresses the editorial comment. Thank you for giving us the opportunity to respond to this comment. A point-by-point description of our response is summarized on page 2 of this letter.

If you have any questions, please feel free to contact me at the address given below.

Sincerely,

Shannon Allen Ferrante, PhD
Health Economic Statistics
Merck Sharp & Dohme Corp
Mailstop: UG1C-60
351 North Sumneytown Pike
Upper Gwynedd, PA 19454-2505
Phone: 267-305-7945
Email: Shannon_ferrante@merck.com
Responses to Reviewers’ Comments

1. Please include the full names of the specific IRBs (institutional review boards) that approved the SPRINT-2 study within the methods section of your manuscript.

There were over 150 institutional review boards (IRBs) that approved the SPRINT-2 protocol and study design. A full list of the IRBs is provided as a supplementary table. In addition, the following text was added to the Methods section.

The study protocol and study design were approved by each of the sites institutional review board and regulatory agencies, and each participant provided written informed consent before undergoing any study-related procedure. A list of the institutional review boards that approved the study protocol and study design is provided in Supplementary Table 1.